98%
921
2 minutes
20
Background: The Recap of atopic eczema (RECAP), a new core outcome of the atopic dermatitis trial, was translated into Japanese and linguistically validated.
Methods: Translation into Japanese was accomplished according to the ISPOR (International Society for Pharmacoeconomics and Outcome Research) guidelines and the basic guidelines for scale translation. The translation process included two forward translations, reconciliation with native English speakers, third-party back translation, cognitive debriefing, review and harmonization by the original authors. Twenty-seven atopic dermatitis and pediatric specialists from 21 centers in Japan participated in the translation process. Cognitive debriefing was conducted through face-to-face interviews using a think-aloud method with the interview guide including questions about comprehensibility, relevance, comprehensiveness, recall period and suggested improvements, based on the COSMIN methodology.
Results: No linguistic or cultural problems were encountered in the translation into Japanese. Cognitive debriefings were conducted with 10 adult patients and 10 parents of pediatric patients. Some minor modifications were made following discussion and approval by the research team and the original authors. The Japanese version of RECAP was considered to be understandable, comprehensive and relevant for adult patients and families of pediatric patients.
Conclusion: The Japanese version of the RECAP, which has been validated as linguistically equivalent to the original version, is now available. Further evaluation of the measurement properties is needed in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.15036/arerugi.72.1240 | DOI Listing |
Acta Derm Venereol
July 2025
Dermatology Hospital, Southern Medical University, Guangzhou, China; School of Public Health, Southern Medical University, Guangzhou, China.
The lack of a validated Chinese version of the Recap of Atopic Eczema questionnaire (RECAP) questionnaire limits its applicability. This prospective study, conducted at a Chinese tertiary hospital between April and November 2024, aimed to evaluate measurement properties of the Chinese RECAP. Participants completed RECAP and reference instruments at baseline, 1-3 days, and 4-6 weeks.
View Article and Find Full Text PDFSkin Health Dis
June 2025
Unit for Paediatric and Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London, London, UK.
Background: Atopic dermatitis (AD) is a common chronic inflammatory skin condition. Currently, there is a lack of real-world evidence regarding the effectiveness of systemic therapies for moderate-to-severe AD. Abrocitinib is a novel Janus kinase 1 selective inhibitor licensed for AD in adults and adolescents requiring systemic treatment.
View Article and Find Full Text PDFActa Derm Venereol
June 2025
Bionorica SE, Neumarkt, Germany.
Atopic dermatitis is a chronic inflammatory skin disease characterized by flare-ups of inflamed, dry, and itchy skin affecting over 200 million people worldwide. "Emollients plus" containing active cosmetic ingredients such as herbal extracts and phytochemicals have the potential to surpass the efficacy of conventional emollients, while avoiding side effects associated with pharmacological interventions. The reported 12-week clinical trial (NCT05790083) evaluated long-term efficacy and tolerability of oil-in-water emulsions BNO 3731 and BNO 3732 containing ginger extract and cannabidiol as basic emollient therapy for atopic dermatitis.
View Article and Find Full Text PDFBr J Dermatol
August 2025
Oregon Health & Science University, Department of Dermatology, Portland, OR, USA.
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set for atopic dermatitis (AD) clinical trials, including four core outcome domains: clinician-reported signs, patient-reported symptoms, eczema control and quality of life. For eczema control, the Atopic Dermatitis Control Tool (ADCT) and the Recap of Atopic Eczema (RECAP) were chosen through consensus methods as equivalent instruments.
Objectives: This study aimed to develop equations to map scores between ADCT and RECAP to facilitate inter-measurement comparison and data synthesis.
J Clin Med
April 2025
Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium.
Evaluating the measurement properties (MPs) of Clinician-Reported Outcome Measures (ClinROMs) is crucial for selecting appropriate instruments for vitiligo assessment. This review critically appraises the existing evidence on the MPs of the ClinROMs used in vitiligo. A systematic search was conducted in PubMed, Embase, and the Cochrane Library up to 20 February 2024, identifying validated ClinROMs in vitiligo.
View Article and Find Full Text PDF